ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of “Buy” by Brokerages

ProQR Therapeutics (NASDAQ:PRQR) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $8.83.

Several research firms have issued reports on PRQR. Raymond James upgraded ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. Chardan Capital reiterated a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. JMP Securities reissued a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. Finally, StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th.

ProQR Therapeutics Stock Performance

Shares of ProQR Therapeutics stock opened at $2.20 on Friday. ProQR Therapeutics has a one year low of $1.61 and a one year high of $4.62. The company has a market cap of $179.70 million, a P/E ratio of -6.88 and a beta of 0.26. The firm has a fifty day moving average of $2.72 and a two-hundred day moving average of $2.58.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. The firm had revenue of $4.22 million during the quarter, compared to analysts’ expectations of $4.75 million. As a group, equities analysts predict that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Institutional Trading of ProQR Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets increased its stake in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 7,300 shares in the last quarter. OneDigital Investment Advisors LLC increased its position in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 15,550 shares in the last quarter. Ballentine Partners LLC purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at $61,000. Finally, Privium Fund Management B.V. lifted its position in shares of ProQR Therapeutics by 0.9% in the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after acquiring an additional 51,663 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).